Nuclear magnetic resonance (NMR) metabolomics was used for identification of metabolic changes in pancreatic cancer (PC) blood plasma samples when compared to healthy controls or diabetes mellitus patients. An increased number of PC samples enabled a subdivision of the group according to individual PC stages and the construction of predictive models for finer classification of at-risk individuals recruited from patients with recently diagnosed diabetes mellitus. High-performance values of orthogonal partial least squares (OPLS) discriminant analysis were found for discrimination between individual PC stages and both control groups. The discrimination between early and metastatic stages was achieved with only 71.5% accuracy. A predictive model based on discriminant analyses between individual PC stages and the diabetes mellitus group identified 12 individuals out of 59 as at-risk of development of pathological changes in the pancreas, and four of them were classified as at moderate risk.

Department of Analytical Chemistry University of Chemistry and Technology Prague 166 28 Prague 6 Czech Republic

Department of Internal Medicine 1st Faculty of Medicine of Charles University and Military University Hospital 169 02 Prague 6 Czech Republic

Institute of Chemical Process Fundamentals of the CAS 165 00 Prague 6 Czech Republic

Laboratory of NMR Spectroscopy University of Chemistry and Technology Prague 166 28 Prague 6 Czech Republic

Zobrazit více v PubMed

Sung H.; Ferlay J.; Siegel R. L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: Cancer J. Clin. 2021, 71, 209–249. 10.3322/caac.21660. PubMed DOI

Nannini G.; Meoni G.; Amedei A.; Tenori L. Metabolomics profile in gastrointestinal cancers: Update and future perspectives. World J. Gastroenterol. 2020, 26, 2514–2532. 10.3748/wjg.v26.i20.2514. PubMed DOI PMC

Sohn T. A.; Lillemoe K. D.; Cameron J. L.; Huang J. J.; Pitt H. A.; Yeo C. J. Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J. Am. Coll. Surg. 1999, 188, 658–669. 10.1016/S1072-7515(99)00049-6. PubMed DOI

Singhi A. D.; Koay E. J.; Chari S. T.; Maitra A. Early Detection of Pancreatic Cancer: Opportunities and Challenges. Gastroenterology 2019, 156, 2024–2040. 10.1053/j.gastro.2019.01.259. PubMed DOI PMC

Hanada K.; Minami T.; Shimizu A.; Fukuhara M.; Yano S.; Sasaki K.; Koda M.; Sugiyama K.; Yonehara S.; Yanagisawa A. Roles of ERCP in the Early Diagnosis of Pancreatic Cancer. Diagnostics 2019, 9, 30.10.3390/diagnostics9010030. PubMed DOI PMC

Costache M. I.; Costache C. A.; Dumitrescu C. I.; Tica A. A.; Popescu M.; Baluta E. A.; Anghel A. C.; Saftoiu A.; Dumitrescu D. Which is the Best Imaging Method in Pancreatic Adenocarcinoma Diagnosis and Staging - CT, MRI or EUS?. Curr. Health Sci. J. 2017, 43, 132–136. 10.12865/CHSJ.43.02.05. PubMed DOI PMC

Balzano G.; Bassi C.; Zerbi A.; Falconi M.; Calori G.; Butturini G.; Leone B. E.; Pederzoli P.; Di Carlo V. Evaluation of UICC TNM classification for pancreatic cancer. Int. J. Pancreatol. 1997, 21, 111–118. 10.1007/BF02822382. PubMed DOI

Mas L.; Schwarz L.; Bachet J. B. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. Curr. Opin. Oncol. 2020, 32, 356–363. 10.1097/CCO.0000000000000639. PubMed DOI

Klaiber U.; Leonhardt C. S.; Strobel O.; Tjaden C.; Hackert T.; Neoptolemos J. P. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbecks Arch. Surg. 2018, 403, 917–932. 10.1007/s00423-018-1724-8. PubMed DOI

Vignoli A.; Ghini V.; Meoni G.; Licari C.; Takis P. G.; Tenori L.; Turano P.; Luchinat C. High-Throughput Metabolomics by 1D NMR. Angew. Chem., Int. Ed. 2019, 58, 968–994. 10.1002/anie.201804736. PubMed DOI PMC

Michálková L.; Horník Š.; Sýkora J.; Habartová L.; Setnička V. Diagnosis of pancreatic cancer via1H NMR metabolomics of human plasma. Analyst 2018, 143, 5974–5978. 10.1039/C8AN01310A. PubMed DOI

Michálková L.; Horník Š.; Sýkora J.; Habartová L.; Setnička V.; Bunganič B. Early Detection of Pancreatic Cancer in Type 2 Diabetes Mellitus Patients Based on 1H NMR Metabolomics. J. Proteome Res. 2021, 20, 1744–1753. 10.1021/acs.jproteome.0c00990. PubMed DOI

Bathe O. F.; Shaykhutdinov R.; Kopciuk K.; Weljie A.; McKay A.; Sutherland F.; Dixon E.; Dunse N.; Sotiropoulos D.; Vogel H. Feasibility of Identifying Pancreatic Cancer Based on Serum Metabolomics. Cancer Epidemiol., Biomark. Prev. 2011, 20, 140–147. 10.1158/1055-9965.EPI-10-0712. PubMed DOI

McConnell Y. J.; Farshidfar F.; Weljie A. M.; Kopciuk K. A.; Dixon E.; Ball C. G.; Sutherland F. R.; Vogel H. J.; Bathe O. F. Distinguishing Benign from Malignant Pancreatic and Periampullary Lesions Using Combined Use of 1H-NMR Spectroscopy and Gas Chromatography-Mass Spectrometry. Metabolites 2017, 7, 3.10.3390/metabo7010003. PubMed DOI PMC

Nishiumi S.; Shinohara M.; Ikeda A.; Yoshie T.; Hatano N.; Kakuyama S.; Mizuno S.; Sanuki T.; Kutsumi H.; Fukusaki E.; Azuma T.; Takenawa T.; Yoshida M. Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics 2010, 6, 518–528. 10.1007/s11306-010-0224-9. DOI

OuYang D.; Xu J.; Huang H.; Chen Z. Metabolomic Profiling of Serum from Human Pancreatic Cancer Patients Using 1H NMR Spectroscopy and Principal Component Analysis. Appl. Biochem. Biotechnol. 2011, 165, 148–154. 10.1007/s12010-011-9240-0. PubMed DOI

Turanli B.; Yildirim E.; Gulfidan G.; Arga K. Y.; Sinha R. Current State of ″Omics″ Biomarkers in Pancreatic Cancer. J. Pers. Med. 2021, 11, 127.10.3390/jpm11020127. PubMed DOI PMC

Urayama S.; Zou W.; Brooks K.; Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun. Mass Spectrom. 2010, 24, 613–620. 10.1002/rcm.4420. PubMed DOI

Zhang L.; Jin H.; Guo X.; Yang Z.; Zhao L.; Tang S.; Mo P.; Wu K.; Nie Y.; Pan Y.; Fan D. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by 1H nuclear magnetic resonance-based metabonomic profiles. Clin. Biochem. 2012, 45, 1064–1069. 10.1016/j.clinbiochem.2012.05.012. PubMed DOI

LaConti J. J.; Laiakis E. C.; Mays A. D.; Peran I.; Kim S. E.; Shay J. W.; Riegel A. T.; Fornace A. J. Jr.; Wellstein A. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma. BMC Genomics 2015, 16, S1.10.1186/1471-2164-16-S1-S1. PubMed DOI PMC

Vernucci E.; Abrego J.; Gunda V.; Shukla S. K.; Dasgupta A.; Rai V.; Chaika N.; Buettner K.; Illies A.; Yu F.; Lazenby A. J.; Swanson B. J.; Singh P. K. Metabolic Alterations in Pancreatic Cancer Progression. Cancers 2020, 12, 2.10.3390/cancers12010002. PubMed DOI PMC

Chenomx NMR Suite, Version 8.5; Chenomx Inc.: Edmonton, Alberta, Canada, 2016.

Benjamini Y.; Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc., Ser. B 1995, 57, 289–300. 10.1111/j.2517-6161.1995.tb02031.x. DOI

R: A Language and Enviroment for Statistical Computing; R Core Team: Vienna, Austria, 2019.

Chong J.; Wishart D. S.; Xia J. Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis. Curr. Protoc. Bioinform. 2019, 68, e8610.1002/cpbi.86. PubMed DOI

Xia J.; Broadhurst D. I.; Wilson M.; Wishart D. S. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 2013, 9, 280–299. 10.1007/s11306-012-0482-9. PubMed DOI PMC

Origin(Pro), Version 2022; Origin Lab Corporation: Northampton, MA, 2022.

Discovery Studio Visualizer, Version 17.2.0.16349; Dassault Systems, BIOVIA: San Diego, CA, 2016.

Long N. P.; Yoon S. J.; Anh N. H.; Nghi T. D.; Lim D. K.; Hong Y. J.; Hong S.-S.; Kwon S. W. A systematic review on metabolomics-based diagnostic biomarker discovery and validation in pancreatic cancer. Metabolomics 2018, 14, 109.10.1007/s11306-018-1404-2. PubMed DOI

Tumas J.; Kvederaviciute K.; Petrulionis M.; Kurlinkus B.; Rimkus A.; Sakalauskaite G.; Cicenas J.; Sileikis A. Metabolomics in pancreatic cancer biomarkers research. Med. Oncol. 2016, 33, 133.10.1007/s12032-016-0853-6. PubMed DOI

Luo X.; Liu J.; Wang H.; Lu H. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis. Pharmacol. Res. 2020, 156, 10480510.1016/j.phrs.2020.104805. PubMed DOI

Son J.; Lyssiotis C. A.; Ying H.; Wang X.; Hua S.; Ligorio M.; Perera R. M.; Ferrone C. R.; Mullarky E.; Shyh-Chang N.; Kang Y. A.; Fleming J. B.; Bardeesy N.; Asara J. M.; Haigis M. C.; DePinho R. A.; Cantley L. C.; Kimmelman A. C. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013, 496, 101–105. 10.1038/nature12040. PubMed DOI PMC

Mayers J. R.; Wu C.; Clish C. B.; Kraft P.; Torrence M. E.; Fiske B. P.; Yuan C.; Bao Y.; Townsend M. K.; Tworoger S. S.; Davidson S. M.; Papagiannakopoulos T.; Yang A.; Dayton T. L.; Ogino S.; Stampfer M. J.; Giovannucci E. L.; Qian Z. R.; Rubinson D. A.; Ma J.; Sesso H. D.; Gaziano J. M.; Cochrane B. B.; Liu S.; Wactawski-Wende J.; Manson J. E.; Pollak M. N.; Kimmelman A. C.; Souza A.; Pierce K.; Wang T. J.; Gerszten R. E.; Fuchs C. S.; Vander Heiden M. G.; Wolpin B. M. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat. Med. 2014, 20, 1193–1198. 10.1038/nm.3686. PubMed DOI PMC

Ananieva E. A.; Wilkinson A. C. Branched-chain amino acid metabolism in cancer. Curr. Opin. Clin. Nutr. Metab. Care 2018, 21, 64–70. 10.1097/MCO.0000000000000430. PubMed DOI PMC

Tumas J.; Baskirova I.; Petrenas T.; Norkuniene J.; Strupas K.; Sileikis A. Towards a Personalized Approach in Pancreatic Cancer Diagnostics Through Plasma Amino Acid Analysis. Anticancer Res. 2019, 39, 2035–2042. 10.21873/anticanres.13314. PubMed DOI

Brand R. E.; Nolen B. M.; Zeh H. J.; Allen P. J.; Eloubeidi M. A.; Goldberg M.; Elton E.; Arnoletti J. P.; Christein J. D.; Vickers S. M.; Langmead C. J.; Landsittel D. P.; Whitcomb D. C.; Grizzle W. E.; Lokshin A. E. Serum biomarker panels for the detection of pancreatic cancer. Clin. Cancer Res. 2011, 17, 805–816. 10.1158/1078-0432.CCR-10-0248. PubMed DOI PMC

Hirata Y.; Kobayashi T.; Nishiumi S.; Yamanaka K.; Nakagawa T.; Fujigaki S.; Iemoto T.; Kobayashi M.; Okusaka T.; Nakamori S.; Shimahara M.; Ueno T.; Tsuchida A.; Sata N.; Ioka T.; Yasunami Y.; Kosuge T.; Kaneda T.; Kato T.; Yagihara K.; Fujita S.; Yamada T.; Honda K.; Azuma T.; Yoshida M. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Clin. Chim. Acta 2017, 468, 98–104. 10.1016/j.cca.2017.02.011. PubMed DOI

Leichtle A. B.; Ceglarek U.; Weinert P.; Nakas C. T.; Nuoffer J. M.; Kase J.; Conrad T.; Witzigmann H.; Thiery J.; Fiedler G. M. Pancreatic carcinoma, pancreatitis, and healthy controls: metabolite models in a three-class diagnostic dilemma. Metabolomics 2013, 9, 677–687. 10.1007/s11306-012-0476-7. PubMed DOI PMC

Ballehaninna U. K.; Chamberlain R. S. Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review. Indian J. Surg. Oncol. 2011, 2, 88–100. 10.1007/s13193-011-0042-1. PubMed DOI PMC

Khomiak A.; Brunner M.; Kordes M.; Lindblad S.; Miksch R. C.; Öhlund D.; Regel I. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Cancers 2020, 12, 3234.10.3390/cancers12113234. PubMed DOI PMC

Moore H. B.; Culp-Hill R.; Reisz J. A.; Lawson P. J.; Sauaia A.; Schulick R. D.; Del Chiaro M.; Nydam T. L.; Moore E. E.; Hansen K. C.; D’Alessandro A. The metabolic time line of pancreatic cancer: Opportunities to improve early detection of adenocarcinoma. Am. J. Surg. 2019, 218, 1206–1212. 10.1016/j.amjsurg.2019.08.015. PubMed DOI

Pannala R.; Basu A.; Petersen G. M.; Chari S. T. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009, 10, 88–95. 10.1016/S1470-2045(08)70337-1. PubMed DOI PMC

Andersen D. K. The practical importance of recognizing pancreatogenic or type 3c diabetes. Diabetes/Metab. Res. Rev. 2012, 28, 326–328. 10.1002/dmrr.2285. PubMed DOI

Li D. Diabetes and pancreatic cancer. Mol. Carcinog. 2012, 51, 64–74. 10.1002/mc.20771. PubMed DOI PMC

Pannala R.; Leirness J. B.; Bamlet W. R.; Basu A.; Petersen G. M.; Chari S. T. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008, 134, 981–987. 10.1053/j.gastro.2008.01.039. PubMed DOI PMC

Diabetes Mellitus in Pancreatic Cancer: A Distinct Approach to Older Subjects with New-Onset Diabetes Mellitus